Register
Login:
Share:
Email Facebook Twitter

EXCLUSIVE: Malcy, Columbus & Reabold presentations - Video Webcast Here

EXCLUSIVE: Leo Koot, Exec Chairman, Columbus Energy speaks at London South East's Oil & Gas event
EXCLUSIVE: Stephen Williams, Reabold Resources speaks at London South East's Oil & Gas event


Epistem Holdings Share Chat (EHP)



There is currently no data for Epistem Holdings.


Share Discussion for Epistem Holdings


Thread View

Please login or register to post a message on Share Chat.

Posts per page:

1
Next Share Chat Page
Ctw2014
Posts: 1,620
Opinion:No Opinion
Price:90.00
RNS
7 Jun '16
Any thoughts?
 
jupiternmars
Posts: 855
Opinion:No Opinion
Price:90.00
Video interview with David Budd
4 May '16
http://tinyurl.com/ho7fhrz

David Budd, chief executive of Epistem Holdings PLC (LON:EHP) says recent tests show its rapid diagnostic system Genedrive is “as accurate as the gold standard”.
Genedrive, which has already launched in India for TB, performed well in EU-funded hepatitis (HCV) study carried out by Institut Pasteur and Hopital Cochin in Paris.
It was 100% accurate in detecting inherited genetic polymorphisms in Hepatitis (HCV) patients compared to the current 'gold-standard' laboratory test, Roche's TaqMan PCR.
“We feel that based on the results that we’ve had today with Institut Pasteur on the qualitative side of detecting HCV that we are in a great position now to go out and find partners that will work with us on commercialising and taking that product to market,” Budd says.
jupiternmars
Posts: 855
Opinion:No Opinion
Price:90.00
Video interview with David Budd
18 Apr '16
http://tinyurl.com/z9crjeq

David Budd, chief executive of Epistem Holdings PLC (LON:EHP) says the news it has reached a major milestone in its development with the full commercial launch of its Genedrive tuberculosis (TB) and antibiotic resistance test, is “hugely significant”.
The company, a specialist in molecular diagnostics and personalised medicine, has teamed up with Xcelris Labs to start selling the product in India.
Next up, Budd says, the company hopes to build up a “menu of tests” over time, now that the company has a “robust technology platform in place”.
Ctw2014
Posts: 1,620
Opinion:No Opinion
Price:95.00
Re excellent
23 Mar '16
Agree. I missed the RNS when it was issued, but a nice $2.9m funding award can't go amiss!
multibag
Posts: 3,116
Opinion:No Opinion
Price:95.00
excellent
21 Mar '16
news folks!
Ctw2014
Posts: 1,620
Opinion:No Opinion
Price:117.50
Nice to see a little bit
18 Feb '16
...of activity with some buys coming through and a small rise in SP.
Ctw2014
Posts: 1,620
Opinion:No Opinion
Price:117.50
RNS
18 Feb '16
Successful assessment of Genedrive enabling clinical trials of hepatitis test in Europe with a view to launch in 2017. Good progress.
Ctw2014
Posts: 1,620
Opinion:No Opinion
Price:112.50
Silent as the grave
17 Feb '16
No other Investors on here?
Ctw2014
Posts: 1,620
Opinion:No Opinion
Price:115.00
RNS 13/1/16
22 Jan '16
New CEO appointed
Ctw2014
Posts: 1,620
Opinion:No Opinion
Price:120.00
RNS 16/12/15
30 Dec '15
Some Directors have been buying. Not massive amounts but respectable. Very good sign that things are ticking along nicely behind the scenes. Could bounce quite well in news IMO, so long as it's good!
Ctw2014
Posts: 1,620
Opinion:No Opinion
Price:135.00
25% spread
9 Nov '15
Really need some news to loosen this up and provide some liquidity
Ctw2014
Posts: 1,620
Opinion:No Opinion
Price:140.00
Very quiet board
30 Oct '15
Is no one else invested here?
Ctw2014
Posts: 1,620
Opinion:No Opinion
Price:140.00
Good price now...
30 Oct '15
..... Wish I was investing now rather than a few months back!
Ctw2014
Posts: 1,620
Opinion:No Opinion
Price:147.50
RNS
28 Oct '15
Preliminary results out.
Ctw2014
Posts: 1,620
Opinion:No Opinion
Price:165.00
Final Results ...
19 Oct '15
...due out on the 28th
Ctw2014
Posts: 1,620
Opinion:No Opinion
Price:200.00
RNS
6 Aug '15
Trading update out. CEO leaves but nice US Govt contract award and cash position looks robust pending roll out of Genedrive in India.
Ctw2014
Posts: 1,620
Opinion:No Opinion
Price:212.50
Bit of a drop here
30 Jul '15
....on no news as far as I can see. Any ideas what's going on?
Ctw2014
Posts: 1,620
Opinion:No Opinion
Price:290.00
RNS
19 May '15
Topped up on this set back which I regard as minor and a buying opportunity.
jupiternmars
Posts: 855
Opinion:No Opinion
Price:317.50
Video interview with CEO Walls
24 Apr '15
http://tinyurl.com/khf7khe

Matthew Walls, chief executive of Epistem (Lon:EHP), says distribution of its handheld TB diagnostic device in India paves the way for other distributor-based deals globally. Walls tells Proactive Investors the test market for TB will be worth US$2bln by 2020, and the biotechnology company’s signature Genedrive tool lends itself to testing all bacterial, viral, fungal and somatic mutations of the body.

Described as 'breakthrough next generation technology' Genedrive is gathering more commercial exposure and Walls says more funds may be required over the next few months to accelerate the device’s push into the global marketplace.
Ctw2014
Posts: 1,620
Opinion:No Opinion
Price:317.50
Regulatory approval letter coming
13 Apr '15
Nice rise this morning on the back of this RNS. Wish I had bought more!
Ctw2014
Posts: 1,620
Opinion:No Opinion
Price:260.00
Punt
10 Apr '15
Just bought a few of these as a bit of a punt. Looks like a good time.
stag1974
Posts: 2,634
Opinion:Strong Buy
Price:277.50
sp
3 Dec '14
my buy showing as a sell mmmm carnt trust buying/selling charts
looks like 2015 1st quarter it could become interesting for this share
comeonvog
Posts: 5,843
Opinion:No Opinion
Price:287.50
RE: ehp
28 Oct '14
looks good to me , what's your thoughts shan
shan
Posts: 6,092
Opinion:No Opinion
Price:287.50
ehp
28 Oct '14
Successful completion of Genedrive® Indian clinical trials and regulatory submission

Epistem Holdings Plc (LSE: EHP), the personalised medicine and biotechnology company, announces today the successful completion of its Genedrive® Indian clinical evaluation study and the regulatory submission with the Drug Controller General of India (DCGI) of its first test for the diagnosis of Tuberculosis and Rifampicin antibiotic resistance (TB). Epistem is now awaiting approval from the Indian regulator for a license to import and sell its first major infectious disease assay for TB, which is anticipated early in 2015.
1
Next Share Chat Page




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.